Most of the reported Mcl-1 inhibitors have poor anti-tumor activity due to poor physical and chemical properties, low mitochondrial membrane penetration, and high serum protein binding rate (Negi and Murphy, 2021; Wang et al., 2021). This evidence concerns the gene MCL1 and neoplasm.